Form 8-K Arcutis Biotherapeutics, For: Aug 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)
August 16, 2024 2:59 PM EDTMizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT)
The analyst comments "For the week ending 08/09/2024, the Zoryve franchise grew 10.5% (vs +4.2% in the prior week) for TRxs and 6.3% (vs +12.4% in the prior week) for... More
